Determination of the Primary Sequence/ Structure

Published

October 15, 2015

Author(s)

Catherine A. Mouchahoir, Mellisa Ly, Michaella Levy, Lisa E. Kilpatrick, Scott C. Lute, Karen W. Phinney, Lisa Marzilli, Kurt A. Brorson, Michael T. Boyne, Darryl Davis, John E. Schiel

Abstract

The primary sequence of a protein, including therapeutic monoclonal antibodies (mAbs), is a critical quality attribute that determines a great deal of its functionality and stability. Significant effort is devoted to determining the complete amino acid sequence of recombinant proteins of potential therapeutic benefit. Several methodologies may be employed to determine the fidelity of transcription and translation of the predicted protein. The focus of this chapter is to demonstrate primary structure confirmation using the recombinant human IgG1ҝ NIST mAb. Mass spectrometry based primary structure determination is covered in this chapter. It also will address the question of what necessary orthogonal characterization (additional enzymes, intact, and/or middle down) should be performed. A historical review of the methods employed to determine the sequence of proteins is included for completeness.

Citation

Current State-of-the-Art and Emerging Technologies for the Analysis of Monoclonal Antibodies

Volume

2

Publisher Info

ACS Publications, Washington, DC

Pub Type

Books

Download Paper

DOI Link

Keywords

NIST mAb, biotherapeutic, monoclonal antibody, primary structure, primary sequence, peptide mapping, top-down, middle-down, bottom-up, intact mass analysis

Citation

Mouchahoir, C. , Ly, M. , Levy, M. , Kilpatrick, L. , Lute, S. , Phinney, K. , Marzilli, L. , Brorson, K. , Boyne, M. , Davis, D. and Schiel, J. (2015), Determination of the Primary Sequence/ Structure, ACS Publications, Washington, DC, [online], https://doi.org/10.1021/bk-2015-1201.ch001 (Accessed October 7, 2024)